½ÃÀ庸°í¼­
»óǰÄÚµå
1546999

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½ÃÀå : ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Á¦Ç° ¹× ±¹°¡º° ºÐ¼® ¹× ¿¹Ãø(2023-2033³â)

Asia-Pacific Continuous Bioprocessing Market: Focus on Application, End User, Product, and Country - Analysis and Forecast, 2023-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½ÃÀå ±Ô¸ð´Â 2023³â 5,100¸¸ ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È 22.50%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³»°í, 2033³â¿¡´Â 3¾ï 8,850¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼öÀ², À¯¿¬¼º, Á¦Á¶¼º, Á¦Ç° Àϰü¼ºÀ» °³¼±ÇÏ°í µ¿½Ã¿¡ Á¦Á¶ ºñ¿ëÀ» Àý°¨ÇÏ¿© ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶¸¦ °³¼±ÇϰíÀÚ ÇÏ´Â ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀϰüµÈ °á°ú¸¦ ¾ò±â À§ÇØ ÃÖ±Ù ¸î ³âµ¿¾È ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀº ¿¬¼Ó ¸ðµå·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
¿¹Ãø ±â°£ 2023-2033³â
2023³â Æò°¡ 5,100¸¸ ´Þ·¯
2033³â Àü¸Á 3¾ï 8,850¸¸ ´Þ·¯
CAGR 22.5%

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½ÃÀåÀº Àü ¼¼°è ¹ÙÀÌ¿À ÀǾàǰ ºÐ¾ß¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇÏ¸ç ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. »ý»ê¼º, ÀûÀÀ¼º, Á¦Ç° ǰÁú Çâ»ó¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ÌÀº ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹ÙÀÌ¿À Á¦Á¶ »ê¾÷À» º¯È­½ÃŰ´Â Àü·«À¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ¼öÀ² Çâ»ó, Á¦Á¶ ºñ¿ë Àý°¨, ½Å·Ú¼º ³ôÀº °íǰÁú Á¦Ç° »ý»ê ´É·Â µî ¸¹Àº ÀÌÁ¡ÀÌ Àֱ⠶§¹®¿¡ ÀÌ Áö¿ª¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ¹ÙÀÌ¿À Á¦¾à ȸ»çµéÀº ÀÌ Àü·«À» ¼±È£Çϰí ÀÖ½À´Ï´Ù.

ÀÌ Áö¿ªÀÇ °­·ÂÇÑ ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶ ÀÎÇÁ¶ó¿Í »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÀÌ Áö¿ª¿¡¼­´Â ¿¬¼ÓÀûÀÎ ¾÷½ºÆ®¸² ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç °­Á¶µÇ°í ÀÖ´Â °ÍÀº ¿¬¼ÓÀûÀÎ ÇÏ·ù ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀ» ÅëÇÕÇÏ¿© Àüü °øÁ¤ÀÇ È¿À²¼ºÀ» ÃÖÀûÈ­ÇÏ°í ¿î¿µÀ» ´õ¿í °£¼ÒÈ­ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕÀº óÀ½ºÎÅÍ ³¡±îÁö ¿øÈ°ÇÑ »ý»ê È帧, ´Ù¿îŸÀÓ °¨¼Ò, ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶ÀÇ È®À强 Çâ»óÀ¸·Î ÀÎÇØ °ÔÀÓ Ã¼ÀÎÀú°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀº ÀÌ Áö¿ªÀÇ R&D¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿Í Á¤ºÎ Àμ¾Æ¼ºê¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹ÙÀÌ¿À ÀǾàǰ ½ÃÀåÀÌ ¼ºÀåÇÔ¿¡ µû¶ó ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ÌÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÃÖ÷´Ü ¹ÙÀÌ¿À Á¦Á¶ ±â¼úÀÇ ¼±±¸Àڷμ­ÀÇ ÀÔÁö¸¦ ±¸ÃàÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ºÐ·ù

¼¼ºÐÈ­ 1: Á¦Ç°º°

  • Å©·Î¸¶Åä±×·¡ÇÇ ½Ã½ºÅÛ ¹× ¼Ò¸ðǰ
  • ¿©°ú ½Ã½ºÅÛ ¹× Àåºñ
  • ¹ÙÀÌ¿À¸®¾×ÅÍ
  • ¼¼Æ÷¹è¾ç ¹èÁö, ¼¼Æ÷ÁÖ, ¿ÏÃæ¾×, ½Ã¾à
  • ±âŸ

¼¼ºÐÈ­ 2: ¿ëµµº°

  • ´ÜÀÏŬ·ÐÇ×ü
  • ¹é½Å
  • ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á
  • ±âŸ

¼¼ºÐÈ­ 3: ÃÖÁ¾ »ç¿ëÀÚº° ¼¼ºÐÈ­

  • Á¦¾àȸ»ç ¹× »ý¸í°øÇÐ ±â¾÷
  • ÇÐ°è ¹× ¿¬±¸±â°ü
  • CRO

¼¼ºÐÈ­ 4: ±¹°¡º°

  • ÀϺ»
  • Àεµ
  • Áß±¹
  • Çѱ¹
  • È£ÁÖ
  • ±âŸ

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, »ê¾÷ µ¿Çâ, ±â¼ú ¹× ƯÇã µ¿Çâ, ±ÔÁ¦ ȯ°æ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎ, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢ ºÎ¹®º°/ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ½ÃÀå

  • µ¿Çâ : ÇöÀç ¹× ÇâÈÄ ¿µÇâ Æò°¡
    • ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½ÃÀå : µ¿Ç⠺м®
    • ¹ÙÀÌ¿ÀÀǾàǰ ¾÷°èÀÇ ¿¬¼Ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì µðÁöÅÐÈ­
    • ÀÏȸ¿ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â±â »ç¿ë Áõ°¡
  • °ø±Þ¸Á °³¿ä
    • ¹ë·ùüÀÎ ºÐ¼®
  • R&D ¸®ºä
    • ƯÇã Ãâ¿ø µ¿Çâ(³ª¶ó¡¤¿¬º°)
  • ±ÔÁ¦ »óȲ
  • ÁÖ¿ä À̺¥Æ®ÀÇ ¿µÇ⠺м® : COVID-19
  • ½ÃÀå ¿ªÇÐ : °³¿ä
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ

Á¦2Àå Áö¿ª

  • Áö¿ªº° °³¿ä
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áö¿ª °³¿ä
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ¿ëµµ
    • Á¦Ç°
    • Áß±¹
    • ¿ëµµ
    • Á¦Ç°
    • Àεµ
    • ¿ëµµ
    • Á¦Ç°
    • È£ÁÖ
    • ¿ëµµ
    • Á¦Ç°
    • ÀϺ»
    • ¿ëµµ
    • Á¦Ç°
    • Çѱ¹
    • ¿ëµµ
    • Á¦Ç°
    • ±âŸ
    • ¿ëµµ
    • Á¦Ç°

Á¦3Àå ½ÃÀå : °æÀï º¥Ä¡¸¶Å·°ú ±â¾÷ °³¿ä

  • ´ÙÀ½ ÇÁ·ÐƼ¾î
  • Áö¿ªÀû Æò°¡
    • OmniBRx Biotechnologies Pvt Ltd.

Á¦4Àå Á¶»ç ¹æ¹ý

LSH 24.09.12

Introduction to Asia-Pacific (APAC) Continuous Bioprocessing Market

The Asia-Pacific continuous bioprocessing market was valued at $51.0 million in 2023 and is expected to reach $388.5 million by 2033, growing at a CAGR of 22.50% between 2023 and 2033. Increased demand to improve biopharmaceutical production through increased yield, flexibility, productivity, and product consistency at the same time as lower manufacturing costs is driving the APAC market for continuous bioprocessing. In order to produce consistent results, bioprocessing has been moving toward continuous mode in recent years. The goal of ongoing efforts is to integrate downstream bioprocessing into a continuous operation, thereby increasing the efficiency and capabilities of the industry, even though continuous upstream bioprocessing has been established and widely adopted.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$51.0 Million
2033 Forecast$388.5 Million
CAGR22.5%

The Asia-Pacific continuous bioprocessing market is expanding quickly as the area assumes a pivotal role in the worldwide biopharmaceutical sector. As the emphasis on improving productivity, adaptability, and product quality grows, continuous bioprocessing is becoming recognized as a game-changing strategy for biomanufacturing in the Asia-Pacific region. Many benefits, such as increased yields, lower manufacturing costs, and the capacity to produce reliable, high-quality products, make this strategy a desirable one for biopharmaceutical companies operating in the area.

The region's strong biopharmaceutical manufacturing infrastructure and the rising demand for novel therapies have led to the widespread adoption of continuous upstream bioprocessing in APAC. The emphasis now is on integrating continuous downstream bioprocessing, optimizing overall process efficiency, and further streamlining operations. With seamless production flows from beginning to end, decreased downtime, and improved scalability of biopharmaceutical production, this integration is predicted to be a game-changer.

The continuous development of bioprocessing technologies is being fueled by the region's substantial investment in research and development as well as encouraging government initiatives. Continuous bioprocessing adoption is expected to pick up speed as the APAC biopharmaceutical market grows, establishing the region as a pioneer in cutting-edge biomanufacturing techniques.

Market Segmentation

Segmentation 1: by Product

  • Chromatography Systems and Consumables
  • Filtration Systems and Devices
  • Bioreactors
  • Cell Culture Media, Cell Lines, Buffers, and Reagents
  • Other Products

Segmentation 2: by Application

  • Monoclonal Antibodies
  • Vaccines
  • Cell and Gene Therapy
  • Other Applications

Segmentation 3: by End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations

Segmentation 4: by Country

  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific continuous bioprocessing market has been segmented based on application, end user, and product. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: In the continuous bioprocessing market, competitive strategy centers around innovation, collaboration, customization, and sustainability. Companies in the market strive to innovate by developing more efficient, scalable, and flexible bioprocessing technologies that reduce production times and costs while maintaining high product quality. Collaboration between equipment manufacturers, biopharmaceutical companies, and research institutions is crucial for sharing knowledge, optimizing processes, and accelerating the adoption of continuous bioprocessing.

Table of Contents

Executive Summary

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Continuous Bioprocessing Market Trend Analysis
    • 1.1.2 Digitization of Continuous Bioprocessing by the Biopharmaceutical Industry
    • 1.1.3 Increasing Use of Single-Use or Disposable Bioprocessing Equipment
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, by Year)
  • 1.4 Regulatory Landscape
  • 1.5 Impact Analysis for Key Events: COVID-19
  • 1.6 Market Dynamics Overview
    • 1.6.1 Market Drivers
      • 1.6.1.1 Growing Demand for Continuous Bioprocessing due to the Flourishing Biopharmaceutical Sector
      • 1.6.1.2 Cost Reduction with Continuous Bioprocessing as Compared to Batch and Fed-Batch Bioprocessing
      • 1.6.1.3 Increasing Adoption of New Technologies like Single-Use Bioprocessing Technology
    • 1.6.2 Market Restraints
      • 1.6.2.1 Technological Complexities and Operational Challenges
      • 1.6.2.2 High Initial Cost Associated with Continuous Bioprocessing
    • 1.6.3 Market Opportunities
      • 1.6.3.1 Numerous Proposed Technologies in Continuous Bioprocessing
      • 1.6.3.2 Moving Closer to End-to-End Continuous Bioprocessing

2 Region

  • 2.1 Regional Summary
  • 2.2 Asia-Pacific
    • 2.2.1 Regional Overview
    • 2.2.2 Driving Factors for Market Growth
    • 2.2.3 Factors Challenging the Market
    • 2.2.4 Application
    • 2.2.5 Product
    • 2.2.6 China
    • 2.2.7 Application
    • 2.2.8 Product
    • 2.2.9 India
    • 2.2.10 Application
    • 2.2.11 Product
    • 2.2.12 Australia
    • 2.2.13 Application
    • 2.2.14 Product
    • 2.2.15 Japan
    • 2.2.16 Application
    • 2.2.17 Product
    • 2.2.18 South Korea
    • 2.2.19 Application
    • 2.2.20 Product
    • 2.2.21 Rest-of-Asia-Pacific
    • 2.2.22 Application
    • 2.2.23 Product

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers
  • 3.2 Geographic Assessment
    • 3.2.1 OmniBRx Biotechnologies Pvt Ltd.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products/Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦